Fast versus slow strategy of switching patients with schizophrenia to aripiprazole from other antipsychotics

Journal of Clinical Psychopharmacology

Volumn 35, Issue 6, 2015, Pages 635-644

  Hwang, Tzung Jeng ^a   Lo, Wei Ming ^b   Chan, Hung Yu ^a,c   Lin, Ching Feng ^b,e   Hsieh, Ming H ^a   Liu, Chen Chun ^a   Liu, Chih Min ^a   Hwu, Hai Gwo ^a   Kuo, Ching Hua ^d   Chen, Wei J ^a,b,e  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c Taoyuan General Hospital Taoyuan   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e National Clinical Trial Statistical Center   (Taiwan)

Author keywords

aripiprazole; efficacy; metabolic profile; prolactin; schizophrenia; switching strategies

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CHOLESTEROL; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; FLURAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; RISPERIDONE; SULPIRIDE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HOSPITALIZATION; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; OPEN STUDY; PARALLEL DESIGN; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QT PROLONGATION; QTC INTERVAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; DRUG ADMINISTRATION; GENETICS; MIDDLE AGED; OUTCOME ASSESSMENT; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84947036344     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000426     Document Type: Article

References (53)

1. Tandon R, Belmaker RH, Gattaz WF, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res. 2008;100:20-38.
2. Turrone P, Kapur S, Seeman MV, et al. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry. 2002;159:133-135.
3. Casey DE. Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry. 2004;65(suppl 18):27-35.
4. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 2007;68(suppl 4):8-13.
5. Chien IC, Hsu JH, Lin CH, et al. Prevalence of diabetes in patients with schizophrenia in Taiwan: a population-based National Health Insurance study. Schizophr Res. 2009;111:17-22.
6. Huang MC, Lu ML, Tsai CJ, et al. Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand. 2009;120:274-280.
7. Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002;441:137-140.
8. Leysen JE, Janssen PM, Schotte A, et al. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology (Berl). 1993;112(suppl 1):S40-S54.
9. Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther. 2000;295:853-861.
10. Bhattacharjee J, El-Sayeh HG. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2008;1:CD006617.
11. Kane JM. Treatment of schizophrenia. Schizophr Bull. 1987;13:133-156.
12. Essock SM, Covell NH, Davis SM, et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry. 2006;163:2090-2095.
13. Weiden PJ. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. J Clin Psychiatry. 2007;68(suppl 4):34-39.
14. Weiden PJ. Switching antipsychotic medications: not enough, too often, or just right? Am J Psychiatry. 2011;168:882-884.
15. Wisniewski CS, Robert S. Strategies for transitioning therapy to aripiprazole from other antipsychotics in schizophrenia. Ann Pharmacother. 2012;46:1097-1104.
16. Tandon R, Marcus RN, Stock EG, et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res. 2006;84:77-89.
17. Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from Olanzapine, Quetiapine, or Risperidone to Aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry. 2011;168:947-956.
18. Takeuchi H, Uchida H, Suzuki T, et al. Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: one-year follow-up study. Psychiatry Clin Neurosci. 2010;64:104-106.
19. Stroup TS, Byerly MJ, Nasrallah HA, et al. Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: Results from a randomized controlled trial. Schizophr Res. 2013;146:190-195.
20. Kinon BJ, Basson BR, Gilmore JA, et al. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiatry. 2000;61:833-840.
21. Peuskens J. Switching approach in the management of schizophrenia patients. Int Clin Psychopharmacol. 2000;15(suppl 4):S15-S19.
22. Takeuchi H, Suzuki T, Uchida H, et al. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering. J Clin Psychopharmacol. 2008;28:540-543.
23. Pae CU, Serretti A, ChiesaA, et al. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. Eur Neuropsychopharmacol. 2009;19:562-570.
24. Molden E, Lunde H, Lunder N, et al. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit. 2006;28:744-749.
25. Laika B, Leucht S, Heres S, et al. Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening? Pharmacogenomics J. 2009;9:395-403.
26. Hendset M, HermannM, Lunde H, et al. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Eur J Clin Pharmacol. 2007;63:1147-1151.
27. Chan HY, Lin WW, Lin SK, et al. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. J Clin Psychiatry. 2007;68:29-36.
28. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64:663-667.
29. Andreasen NC, Pressler M, Nopoulos P, et al. Antipsychotic dose equivalents and dose-years: A standardized method for comparing exposure to different drugs. Biol Psychiatry. 2010;67:255-262.
30. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003;166:391-399.
31. Cheng JJ, Ho H, Chang CJ, et al. Positive and Negative Syndrome Scale (PANSS): establishment and reliability study of a Mandarin Chinese language version. Chinese Psychiatry. 1996;10:251-258.
32. Guy W. Clinical Global Impression (CGI). In: Guy W, ed. Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology. Rockville, MD: National Institute ofMental Health: US Department of Health, Education and Welfare Publication (Pub No. ADM 76-338); 1976:218-222.
33. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. In: Acta Psychiatr Scand. 1970;212:11-19.
34. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
35. Guy W. Abnormal Involuntary Movement Scale (AIMS). In: Guy W, ed. Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology. Rockville, MD: National Institute ofMental Health: US Department of Health, Education and Welfare Publication (Pub No ADM 76-338); 1976:534-537.
36. Sweet RA, DeSensi EG, Zubenko GS. Reliability and applicability of movement disorder rating scales in the elderly. J Neuropsychiatry Clin Neurosci. 1993;5:56-60.
37. Caligiuri MP, Lacro JP, Jeste DV. Incidence and predictors of drug-induced Parkinsonism in older psychiatric patients treated with very low doses of neuroleptics. J Clin Psychopharmacol. 1999;19:322-328.
38. Loonen AJ, van Praag HM. Measuring movement disorders in antipsychotic drug trials: the need to define a new standard. J Clin Psychopharmacol. 2007;27:423-430.
39. Al-Khatib SM, LaPointe NM, Kramer JM, et al. What clinicians should know about the QT interval. JAMA. 2003;289:2120-2127.
40. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5:6-13.
41. Liu CH, Peck K, Huang JD, et al. Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip. Pharmacogenomics. 2005;6:731-747.
42. Walker GA. Common StatisticalMethods for Clinical Research with SAS® Examples. 2nd ed. Cary, NC: SAS Institute Inc; 2002.
43. Markowitz JC, Skodol AE, Petkova E, et al. Longitudinal effects of personality disorders on psychosocial functioning of patients with major depressive disorder. J Clin Psychiatry. 2007;68:186-193.
44. Mitchell AJ, Vancampfort D, Sweers K, et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis. Schizophr Bull. 2013;39:306-318.
45. Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am. 2008;37:67-99.
46. Sparshatt A, Taylor D, Patel MX, et al. A systematic review of aripiprazole-dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry. 2010;71:1447-1456.
47. Kubo M, Koue T, Maune H, et al. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet. 2007; 22:358-366.
48. Ryckmans V, Kahn JP, Modell S, et al. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study. Pharmacopsychiatry. 2009;42:114-121.
49. Aitchison KJ, Bienroth M, Cookson J, et al. A UK consensus on the administration of aripiprazole for the treatment of mania. J Psychopharmacol. 2009;23:231-240.
50. Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. J Clin Psychiatry. 2007;68(suppl 6):10-13.
51. Sullivan G, Bienroth M, Jones M, et al. Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel. Curr Med Res Opin. 2007;23:1733-1744.
52. Travis MJ, Burns T, Dursun S, et al. Aripiprazole in schizophrenia: consensus guidelines. Int J Clin Pract. 2005;59:485-495.
53. Takase M, Kanahara N, Oda Y, et al. Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia. J Psychopharmacol. 2015;29:383-389.